GSTCD and INTS12 regulation and expression in the human lung by Obeidat, Ma’en et al.
GSTCD and INTS12 Regulation and Expression in the
Human Lung
Ma’en Obeidat1,4☯, Suzanne Miller1☯, Kelly Probert1, Charlotte K. Billington1, Amanda P. Henry1, Emily
Hodge1, Carl P. Nelson1, Ceri E. Stewart1, Caroline Swan1, Louise V. Wain2, María Soler Artigas2, Erik
Melén3, Kevin Ushey4, Ke Hao5, Maxime Lamontagne7, Yohan Bossé6,7, Dirkje S. Postma8, Martin D.
Tobin2,9, Ian Sayers1, Ian P. Hall1*
1 Division of Respiratory Medicine, University of Nottingham, Queen’s Medical Center, Nottingham, United Kingdom, 2 Genetic Epidemiology Group,
Department of Health Sciences, University of Leicester, Leicester, United Kingdom, 3 Institute of Environmental Medicine, Karolinska Institutet and Sachs’
Children’s Hospital, Stockholm, Sweden, 4 James Hogg Research Centre, Institute for Heart and Lung Health, University of British Columbia, Vancouver, British
Columbia, Canada, 5 Department of Genetics and Genomic Sciences, Icahn Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount
Sinai, New York, United States of America, 6 Department of Molecular Medicine, Laval University, Québec City, Canada, 7 Institut Universitaire de Cardiologie
et de Pneumologie de Québec, Laval University, Québec City, Canada, 8 Department of Pulmonology, University of Groningen, University Medical Center
Groningen, Groningen, The Netherlands, 9 National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Research Unit, Glenfield Hospital,
Leicester, United Kingdom
Abstract
Genome-Wide Association Study (GWAS) meta-analyses have identified a strong association signal for lung
function, which maps to a region on 4q24 containing two oppositely transcribed genes: glutathione S-transferase, C-
terminal domain containing (GSTCD) and integrator complex subunit 12 (INTS12). Both genes were found to be
expressed in a range of human airway cell types. The promoter regions and transcription start sites were determined
in mRNA from human lung and a novel splice variant was identified for each gene. We obtained the following
evidence for GSTCD and INTS12 co-regulation and expression: (i) correlated mRNA expression was observed both
via Q-PCR and in a lung expression quantitative trait loci (eQTL) study, (ii) induction of both GSTCD and INTS12
mRNA expression in human airway smooth muscle cells was seen in response to TGFβ1, (iii) a lung eQTL study
revealed that both GSTCD and INTS12 mRNA levels positively correlate with percent predicted FEV1, and (iv) FEV1
GWAS associated SNPs in 4q24 were found to act as an eQTL for INTS12 in a number of tissues. In fixed sections
of human lung tissue, GSTCD protein expression was ubiquitous, whereas INTS12 expression was predominantly in
epithelial cells and pneumocytes. During human fetal lung development, GSTCD protein expression was observed to
be highest at the earlier pseudoglandular stage (10-12 weeks) compared with the later canalicular stage (17-19
weeks), whereas INTS12 expression levels did not alter throughout these stages. Knowledge of the transcriptional
and translational regulation and expression of GSTCD and INTS12 provides important insights into the potential role
of these genes in determining lung function. Future work is warranted to fully define the functions of INTS12 and
GSTCD.
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Introduction
Forced expiratory volume in one second (FEV1), forced vital
capacity (FVC), and the ratio of FEV1 to FVC (FEV 1/FVC) are
commonly used to assess pulmonary function and these
measurements are integral to the diagnosis of chronic
obstructive pulmonary disease (COPD). Reduced FEV 1/FVC
defines airway obstruction, whereas reduced FEV1 grades the
severity of airway obstruction [1]. These measures also predict
population morbidity and mortality [2].
Pulmonary function is determined both by environmental and
genetic factors. Tobacco smoking is the major environmental
risk factor for the development of COPD in the developed
world. A genetic contribution to pulmonary function is well
established with heritability estimates reaching as high as 77%
for FEV1 [3]. Three large scale meta-analyses of genome-wide
association studies (GWAS) of lung function measures have
recently been published [4-6]: these studies identified a total of
26 novel loci associated with either FEV1 or FEV 1/FVC.
Genome-wide interaction analyses with smoking later identified
three additional regions of potential importance for lung
function [7]. One of the strongest association signals identified
was with intronic Single Nucleotide Polymorphisms (SNPs) in a
region at 4q24 containing two oppositely transcribed genes:
glutathione S-transferase, C-terminal domain containing
(GSTCD) and integrator complex subunit 12 (INTS12). In the
SpiroMeta study [5], SNP rs10516526 in intron 5 of GSTCD
was associated with FEV1 (P=2.18x10-23 in the joint meta-
analysis of discovery and replication cohorts (n=53,309)). In the
combined SpiroMeta CHARGE meta-analysis with larger
sample size (discovery n=48,201), SNP rs10516526 also
showed the strongest association in the 4q24 locus for FEV1
(P=4.75x10-14) [6]. Subsequent reports by SpiroMeta
investigators and others have also implicated this locus for
association with COPD [8,9].
At present, little is known about the potential function of
GSTCD – all four entries on PubMed are related to recent
GWAS studies [4,5,8,9]. GSTCD is so named because of
homology with the glutathione S-transferase (GST) super
family of enzymes [10]. GSTs are also involved in the
detoxification of products of oxidative stress [11] and synthesis
of steroid hormones. They also have an increasingly
appreciated role in cell signalling pathways including regulation
of Jun N-terminal kinase and the modulation of ryanodine
receptor calcium channels [10,12]. However, GSTCD lacks key
functional domains important for GST activity. Although still
only appearing in a handful of (largely GWAS-related)
publications [4,8,13], more is known about the function of
INTS12, which is a subunit of the Integrator complex. This
complex associates with the C-terminal domain of RNA
polymerase II large subunit and mediates 3` end processing of
small nuclear RNAs [14].
Additional evidence linking GSTCD to variation in lung
function came from a study reporting human lung mRNA
correlation with lung function [15]. In this study, which
undertook genome-wide expression profiling, GSTCD mRNA
levels were associated with percent predicted FEV1 (Spearman
correlation=0.44, P=0.001) and the FEV 1/FVC ratio (Spearman
correlation=0.48, P=0.0002) [15]. This, and the fact that the
4q24 locus has the strongest novel association with lung
function in the multiple GWAS meta-analyses conducted so far,
have provided the rationale to further investigate this locus to
unravel the mechanisms underlying this association.
Here we report the genetic architecture of GSTCD and
INTS12, and show that both genes are expressed in a range of
cell types present in the lung. We report one novel splice
variant for each gene. Furthermore we show that the genome-
wide significant SNPs at 4q24 act as expression quantitative
trait loci (eQTL) for INTS12, and provide evidence that the
peak association signal maps to a region rich in elements likely
to be important for transcriptional regulation of these genes.
Interestingly, these appear to be coordinately regulated in the
lung. Expression levels were also shown to correlate with lung
function measures. Finally, we describe the expression of
GSTCD and INTS12 proteins in human lung tissue and assess
how expression is altered during human fetal development.
Results
Gene arrangement via PCR and RACE
Using cDNA synthesised from RNA extracted from total lung,
human airway smooth muscle (HASM) cells and normal human
bronchial epithelial cells (HBEC), Reverse Transcription (RT)-
PCR was initially performed to investigate whether gene
arrangements are consistent with those reported by NCBI (the
National Center for Biotechnology Information). For both
GSTCD and INTS12 a novel splice variant was discovered via
this method (named here “variant 3”). Figure 1 outlines
schematically the two published variants in addition to the
novel variant 3 in each case. The SpiroMeta genome-wide
significant SNPs for association with FEV1 in this locus are
annotated on the schematic in Figure 1 along with the relevant
association statistical P values [5].
To confirm published or reveal novel transcription start site
(TSS) s for both GSTCD and INTS12, Rapid Amplification of
cDNA Ends (RACE) was performed. For GSTCD, a total of 30
clones were sequenced and analysed. 5’ RACE confirmed the
presence of variant 2 (NM_024751.2) in 13 of these (43%),
albeit with multiple TSSs spanning a region of 50bp; minimum
+3, maximum +53bp distance relative to RefSeq (TSS) at
106629941 (hg build 37) (Figure S1A). The annotated
nucleotide sequence showing TSSs in both GSTCD and
INTS12 can be found in Figure S1. Interestingly, variant 1 of
GSTCD (NM_001031720.2) was not identified in any of the 30
RACE clones analysed. Sequence reads did confirm the novel
variant 3 identified via RT-PCR for GSTCD in 17 clones out of
the 30 analysed (56%) (Figure S1B). Variant 3 sequence
mapped to the first exon of variant 2 and the second exon of
variant 1. Three different TSSs were identified in variant 3
spanning a region of 27bp; the first was identical to the RefSeq
exon 1 (3/30 clones = 10%), the second was the most common
(12/30 clones = 40%) and had a 10bp shorter exon 1, the third
and least frequent had a 27bp shorter exon 1 (2/30 clones=
6.7%) (Figure S1A and B).
To confirm the absence of exon 1 of GSTCD variant 1 in the
lung tissue, a different RT-PCR protocol was designed with
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primers spanning this exon and a sequence in exon 3, common
to both variants. No PCR product for this assay was detected in
a panel of airway-related cell types after 40 cycles of PCR
(Figure S2).
For INTS12, the 5’ RACE using RNA from lung tissue
confirmed the presence of variant 2 with multiple TSSs over a
region of ~30bp; minimum 36 and maximum 60bp upstream
(distance relative to the RefSeq build 37 TSS at 106629881).
Variant 1 (NM_020395.3) was not observed in any of the 31
clones analysed. The most common variant 2 transcript
identified was a 60bp truncated first exon (18/31 clones =
58%), relative to the RefSeq. 50bp and 36bp truncations of
exon 1 were also identified with frequencies of 23 and 19%,
respectively (Figure S1C).
As shown in Table 1, both GSTCD and INTS12 feature on
NCBI as existing in two variants. GSTCD variants 1 and 2
encode two proteins differing in length by 87 amino acids. This
is the result of a truncated second exon meaning that amino
acids 55 to 141 of variant 1 are absent in variant 2. Unlike
GSTCD, the two INTS12 transcripts both encode the same
protein. If translated, the INTS12 variant 3 would result in a
truncated protein of 237 residues (versus 462 residues for
variants 1 and 2), due to a premature translational stop codon
present in the additional exon between exons 5 and 6 (shown
boxed in red in Figure 1). The resulting protein isoform retains
the PHD-type zinc finger, but lacks the serine-rich region.
Searches to identify proteins sharing homology with the
GSTCD and INTS12 variants are shown in Table S1 (A-C) and
summarised in the discussion.
Re-sequencing of the GSTCD/INTS12 region
In two separate studies (results currently unpublished), re-
sequencing experiments were performed to investigate the
effects of novel or rare SNPs on lung function. We extracted
information on SNPs measured in these studies within GSTCD
and INTS12 to identify whether there were any SNPs which
were novel or not included in the previously used (i.e. HapMap)
Figure 1.  Genetic architecture of the region containing both GSTCD and INTS12 genes.  The top panel depicts gene
arrangements previously reported in NCBI, build 37, whereas the lower panel shows novel variants identified in lung. V1, 2, 3 refer
to splice variants 1, 2 and 3 for each gene. Open boxes represent exons and connecting black lines represent introns. Also
illustrated are the locations of Single Nucleotide Polymorphisms (SNPs) meeting genome-wide association (P≤5x10-8) for FEV1 in
previously reported analyses of the SpiroMeta consortium [5]. Highlighted in red is the sentinel SNP rs10516526 that was
associated with FEV1 (P=2.18 x 10-23 in all stage analyses) [5]. Translation start codons (ATG) are shown boxed in green and stop
codons (TAA) boxed in red.
doi: 10.1371/journal.pone.0074630.g001
GSTCD and INTS12 Regulation in the Human Lung
PLOS ONE | www.plosone.org 3 September 2013 | Volume 8 | Issue 9 | e74630
or next generation (i.e. 1000 Genomes Project) SNP imputation
reference panels used for genome-wide association studies of
the genetic determinants of lung function. An exome re-
sequencing project using DNA from 100 individuals with normal
FEV1 despite many years of heavy smoking (see Table S2A)
identified 1 non-synonymous SNP (rs146172950) and 1
synonymous SNP (rs144650579) in the coding region of
INTS12 which were listed in dbSNP v137 but which were not in
the 1000 Genomes Project imputation reference panel [16]. All
SNPs appeared in the 1000 Genomes Project imputation
reference panel in exonic GSTCD. In addition a targeted
sequencing study in both controls and subjects with COPD that
focused on 26 regions known to affect lung function [4,5,9] (see
Table S2B) identified two intronic SNPs in GSTCD that do not
appear in the 1000 Genomes Project imputation reference
panel. One of them is listed in dbSNP v137 (rs113987854) and
the other is not. None of these SNPs were in the widely used
HapMap imputation panels and so would not have been
studied in imputed genome-wide association studies
undertaken to date. These data provide some evidence for
variation in GSTCD that is not currently included in the next
generation of widely used imputation reference panels of
SNPs.
GSTCD/INTS12 in the University of California Santa
Cruz (UCSC) Genome Browser
Due to the close proximity of the GSTCD and INTS12 genes,
we investigated current knowledge regarding the regulation of
this region through bioinformatic searches including data and
tracks generated from the ENCODE project [17]. Figure 2
shows the “Regulation” tracks from the UCSC Genome
Browser (http://genome.ucsc.edu/). It is interesting to note the
histone modification activity in this region is expressed as
acetylation of lysine 27 of the H3 histone protein; this is usually
associated with enhanced transcription and active promoters in
mammalian cells [18]. Also shown in Figure 2 is a CpG island
(bottom track). An expansion of this region reveals the CpG
island to be 639bp long: this encompasses the intergenic
region between GSTCD and INTS12, and parts of the first exon
of both genes. The UCSC Genome Browser defines a CpG
island as a region of at least 200bp, with a GC percentage
>50%, and an observed/expected CpG ratio >60%. CpG
Table 1. Protein variants of GSTCD and INTS12,
corresponding mRNAs.
Gene Variant mRNA Protein Amino acid length
GSTCD 1 NM_001031720.3 NP_001026890.2 633
 2 NM_024751.3 NP_079027.2 546
 3 NK NK 633
INTS12 1 NM_020395.3 NP_065128 462*
 2 NM_001142471.1 NP_001135943  
 3 NK NK 237
Based on NCBI gene database accessed November 2012. NK: Not Known; * Both
variants encode the same protein.
doi: 10.1371/journal.pone.0074630.t001
islands are classically associated with transcription start sites
and are found in ~70% of annotated promoters [19].
Expression of GSTCD and INTS12 mRNA in human
airway cells and lung tissue
We have previously reported that GSTCD is identified in lung
and airway-related cell types at the mRNA level using RT-PCR
[5], however the presence of INTS12 was not assessed. The
relative expression of GSTCD and INTS12 was therefore
determined in a panel of airway-related cell types using
quantitative RT-PCR (Q-PCR). Whole human lung, cultured
HASM cells, cultured HBEC and peripheral blood mononuclear
cells (PBMC) were studied (Figure 3A). Mean expression data
are presented relative to the whole lung sample for each tissue/
cell type. The highest expression of both GSTCD and INTS12
was seen in HBEC, with GSTCD showing relatively higher
expression in this cell type than INTS12. The lowest GSTCD
expression was detected in PBMC, while for INTS12 the lowest
expression was detected in the whole lung samples. Ct values
observed for GSTCD and INTS12 were generally comparable,
and the efficiency standard curves for both genes were also
similar (data not shown). Interestingly, delta Ct values of both
genes presented as a scatter plot (Figure 3B) showed a
moderate degree of correlation (r=0.64, P<0.0001) suggesting
expression may be coordinately regulated. To verify this, we
investigated the correlation between the GSTCD and INTS12
probe sets in 1,111 human lung specimens from the lung eQTL
study [20]. The results presented in Table 2 show good positive
correlation between the GSTCD and INTS12 probe sets in
agreement with that observed via Q-PCR. The strongest
correlation observed was between probe set
100139146_TGI_at (INTS12) and probe set
100312817_TGI_at (GSTCD) (r=0.18, P=6.7E-10); a scatter
plot of these data is shown in Figure 3C.
Altered expression of GSTCD and INTS12 mRNA by
TGFβ1
Further evidence of coordinated expression came from a
series of experiments to determine which signalling pathways
could modulate mRNA levels of GSTCD and INTS12 in HASM
and HBEC, as assessed by Q-PCR. A range of agents was
selected, each known to mediate common cell signalling
pathways, particularly with a focus on those associated with
airway dysfunction. The agents utilised were bradykinin
(elevator of intracellular Ca2+), forskolin (activator of adenylyl
cyclase and hence the pro-relaxant cyclic AMP pathway),
lipopolysaccharide (LPS) (used as a mimic of bacterial
infection), transforming growth factor β1 (TGFβ1) (a key
cytokine, found to be elevated in airway inflammation, and in
COPD) and the Extracellular Signal-Regulated Kinase (ERK)
inhibitor U0126. None of the agents induced a significant
alteration in the levels of mRNA expression of either gene in
HBEC. In addition, of all the panel of reagents utilised, only
exposure to TGFβ1 induced a significant change in mRNA
expression in HASM cells, however this was observed for both
genes (Figure 4). Significant increases in mRNA expression in
HASM cells were observed following 24h exposure to TGFβ1 in
both GSTCD (1.56 ± 0.2 fold cf vehicle control, n=5, P<0.05)
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and INTS12 (2.26 ± 0.3 fold cf vehicle control, n=5, P<0.01)
while a significant increase in INTS12 was also observed
following 4h TGFβ1 exposure (2.0 ± 0.2 fold cf vehicle control,
n=5, P<0.05). To investigate the possible transcriptional
mechanisms driving these observed differences, ENCODE
data from the UCSC Genome Browser were utilised to
investigate transcription factor binding as determined through
ChIP-seq (chromatin immunoprecipitation with antibodies
specific to the transcription factor followed by sequencing of the
precipitated DNA). A number of transcription factor binding
sites were identified in the intergenic region between GSTCD
and INTS12 and in the gene 5’ regions (Table S3) and the
potential relevance of these is covered in the Discussion.
Identifying eQTL in the GSTCD/INTS12 locus
To gain further insight into the mechanisms underlying the
GWAS signal on 4q24, we investigated the presence of eQTL
in this locus using publically available eQTL sources, and also
through access to a lung tissue-specific eQTL dataset in
collaboration with the lung eQTL study group [20].
We investigated eQTL in the 4q24 locus via the eQTL
website at http://www.hsph.harvard.edu/liming-liang/software/
eqtl/ using the lymphoblastoid cell line dataset from Liang et al.
[21]. Interestingly, using this dataset we identified an eQTL for
INTS12 that met the 0.05 false discovery rate (FDR) (probe set
218616_at). There were no significant eQTL for GSTCD, NPNT
or FLJ20184 (Figure S3A).
In addition, we investigated eQTL in the 4q24 region using
the University of Chicago eQTL website at http://
eqtl.uchicago.edu/Home.html which hosts a browser
summarising results from a collection of published eQTL
studies. The results shown in Figure S3B, are similar to the
Liang et al., data suggesting the presence of eQTL for INTS12
in eQTL studies utilising different tissue types. We then
extracted the associations of INTS12 eQTL with FEV1 in the
SpiroMeta dataset, and interestingly the majority of INTS12
eQTL show genome-wide significant associations with FEV1 in
the SpiroMeta dataset. The INTS12 eQTL and their
associations with FEV1 are shown in Table 3. Additionally, we
checked the potential function of INTS12 eQTL in the ENCODE
Figure 2.  Regulatory motifs within the GSTCD/INTS12 locus.  The GSTCD/INTS12 locus is shown, annotated with RNA
sequencing, H3K27Ac histone marks, DNase hypersensitivity, transcription factor binding and CpG islands (UCSC Genome
Browser (http://genome.ucsc.edu/)) on the Human Feb 2009 (GRCh37/hg19) assembly. For the H3K27Ac histone marks and RNA
sequence tracks, peak height is proportional to signal amplitude, with colours representing datasets in different cell backgrounds
(pale blue H3K27Ac histone trace = human umbilical vein endothelial cell (HUVEC); blue/grey = K562 erythroleukaemia cells). For
the DNase hypersensitivity and transcription factor binding tracks, a grey band indicates the extent of the hypersensitive region and
the intensity of the band is proportional to the maximum signal strength observed in any cell line.
doi: 10.1371/journal.pone.0074630.g002
GSTCD and INTS12 Regulation in the Human Lung
PLOS ONE | www.plosone.org 5 September 2013 | Volume 8 | Issue 9 | e74630
Figure 3.  A: Expression of GSTCD and INTS12 mRNA in Lung and Airway cells.  mRNA expression in human airway smooth
muscle (HASM) cells, human bronchial epithelial cells (HBEC) and peripheral blood mononuclear cells (PBMC) is shown relative to
mRNA from lung. Open bars depict GSTCD expression whereas black bars show INTS12 expression. Values shown are mean and
standard error of the mean (SEM) (n=3). Only the expression of GSTCD in HBEC relative to lung was statistically significant (*
P=0.0494). B: Correlation between GSTCD and INTS12 ΔCt values in HASM, HBEC, PBMC and lung. mRNA expression levels
as shown in Figure 3A from human airway smooth muscle (HASM) cells, human bronchial epithelial cells (HBEC), peripheral blood
mononuclear cells (PBMC) and lung were correlated using a scatter plot. The correlation coefficient between these measures was
r=0.8, P<0.0001. C: Correlation between GSTCD and INTS12 mRNA levels in the lung. The scatter plot shows a positive
correlation between the GSTCD and INTS12 probe sets as investigated in the lung eQTL study [20].
doi: 10.1371/journal.pone.0074630.g003
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dataset using HaploReg v2. These eQTL appear to span
regions with either known protein binding motifs, enhancers,
promoters or DNase hypersensitivity sites. Results are shown
in Table S4. In collaboration with the lung eQTL study [20] we
aimed to identify eQTL for GSTCD and INTS12 in the human
lung using a dataset of genome-wide genotypes and gene
expression profiles from the lungs of 1,111 individuals that has
recently been published [20]. There were no lung eQTL for
GSTCD or INTS12 that pass the 0.1 FDR threshold set in the
Table 2. Correlation coefficients and P values for GSTCD
and INTS12 probe sets in 1,111 individuals from the lung
eQTL study.
GSTCD probe sets INTS12_100139146_TGI_at
 Pearson correlation Pearson P value
GSTCD_100156283_TGI_at  0.145 1.29E-06
GSTCD_100147268_TGI_at -0.058 0.05151
GSTCD_100312817_TGI_at 0.184 6.67E-10
doi: 10.1371/journal.pone.0074630.t002
lung eQTL study. The eQTL identified for GSTCD and INTS12
in the lung are shown in Figure S4 which suggest a stronger
eQTL signal for INTS12, albeit not significant when correcting
for multiple comparisons.
Correlation of GSTCD and INTS12 mRNA levels in the
lungs with percent predicted FEV1
Three probe sets targeting GSTCD and one probe set for
INTS12 were utilised in the lung eQTL study. The correlation
measures of these probe sets with percent predicted FEV1 are
shown in Figure 5. One of the GSTCD probe sets
(100156283_TGI_at, r=0.14, P=6.74x10-5) and the INTS12
probe set (r=0.13, P=1.95x10-4) show reasonable correlation
with percent predicted FEV1, although the correlation was more
statistically significant with the GSTCD probe set. Moreover,
the direction of correlations is such that higher mRNA levels
correlate with better lung function indicated by higher percent
predicted FEV1. Table S5 shows the demographics of the
individuals which participated in this study.
Figure 4.  GSTCD and INTS12 gene expression is altered following exposure of HASM cells to TGFβ1.  Human airway
smooth muscle (HASM) cells were exposed to 10ng/ml TGFβ1 for 4 or 24 hours. Open bars depict GSTCD expression whereas
black bars show INTS12 expression. Values shown are mean and standard error of the mean (SEM) (n=5). Significant increases in
both GSTCD and INTS12 gene expression were observed following 24h exposure to TGFβ1 (P<0.05 GSTCD, P<0.01 INTS12) and
after 4h TGFβ1 exposure in INTS12 expression (P<0.05).
doi: 10.1371/journal.pone.0074630.g004
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Table 3. INTS12 eQTL identified in multiple tissue types
and their association with FEV1 in the SpiroMeta study.
LCL: lymphoblastoid cell lines.
SNP Position
FEV1 P
value
eQTL P
value or
significance Tissue Reference
rs1005015
9 106985364 7.23E-09 6.59E-08 LCL [21]
rs1005033
3 106985262 7.22E-09 6.55E-08 LCL  
rs1051652
5 106887474 1.44E-09 9.96E-08 LCL  
rs1051652
5 106887474 1.44E-09
0.014
(posterior
probability)
LCL [40]
rs1051652
5 106887474 1.44E-09 1.30E-07 Liver [41]
rs1051652
6 106908353 6.67E-10 9.94E-08 LCL [21]
rs1051652
7 106953795 6.49E-09 4.66E-08 LCL  
rs1051652
8 106959042 6.27E-09 6.48E-08 LCL  
rs1109790
1 106949382 6.32E-09 4.64E-08 LCL  
rs1172222
5 106985879 7.08E-09 6.60E-08 LCL  
rs1172322
5 106965514 6.02E-09 6.37E-08 LCL  
rs1172483
9 106857705 1.79E-09 9.94E-08 LCL  
rs1172483
9 106857705 1.79E-09
0.036
(posterior
probability)
LCL [40]
rs1172612
4 106985945 6.63E-09 6.63E-08 LCL [21]
rs1172656
9 106826057 1.95E-09
0.075
(posterior
probability)
LCL [40]
rs1172718
9 106838589 3.38E-09 1.03E-07 LCL [21]
rs1172773
5 106851319 2.10E-09 9.94E-08 LCL  
rs1172773
5 106851319 2.10E-09
0.14
(posterior
probability)
LCL [40]
rs1172774
5 106935976 5.47E-09 5.27E-08 LCL [21]
rs1172804
4 106824235 1.95E-09 1.05E-07 LCL  
rs1172804
4 106824235 1.95E-09
0.185
(posterior
probability)
LCL [40]
rs1172871
6 106975445 8.44E-09 1.28E-07
Cortex
(Brain) [42]
Expression of GSTCD and INTS12 protein in human
lung
Having dissected the genetic architecture of GSTCD and
INTS12 and explored their regulation at the mRNA level, we
next investigated expression at the protein level in the human
airways. In addition to utilising samples from non-diseased
sections of human lungs, we assessed expression of both
proteins in individuals with COPD and also in human lung at a
range of fetal developmental stages.
Figure 6 shows representative images of the expression of
GSTCD (6A) and INTS12 (6B) in control donors (panels a and
e) and in lung samples from individuals with COPD (panels b
and f). In controls, GSTCD was observed to be expressed
ubiquitously, being most evident in the pneumocytes of alveolar
regions (Figure 6A, image a) and in the bronchial epithelium
Table 3 (continued).
SNP Position
FEV1 P
value
eQTL P
value or
significance Tissue Reference
rs1173141
7 106965461 5.96E-09 4.86E-08 LCL [21]
rs1173265
0 106973680 6.83E-09 5.02E-08 LCL  
rs1173322
5 106924812 2.34E-09 8.43E-08 LCL  
rs1173328
7 106924788 2.32E-09 8.47E-08 LCL  
rs1173365
4 106950159 0.0358 4.62E-08 LCL  
rs1173585
1 106916703 1.90E-09 8.95E-08 LCL  
rs1173685
9 106928234 2.86E-09 8.08E-08 LCL  
rs1237425
6 106836810 1.88E-09 1.04E-07 LCL  
rs1237425
6 106836810 1.88E-09
0.047
(posterior
probability)
LCL [40]
rs1703609
0 106813023 3.84E-08 1.70E-07
Cortex
(Brain) [42]
rs1703613
9 106852106 1.25E-09
0.057
(posterior
probability)
LCL [40]
rs1703613
9 106852106 1.25E-09 1.07E-07
Cortex
(Brain) [42]
rs1703614
2 106854185 1.11E-09
0.049
(posterior
probability)
LCL [40]
rs1703614
2 106854185 1.11E-09 2.56E-08
Cortex
(Brain) [42]
rs1703622
5 106929541 3.33E-09 4.88E-08
Cortex
(Brain)  
rs6820671 106833270 1.31E-05 2.88E-05 Liver [43]
rs7676975 106983260 6.75E-09 5.18E-08 LCL [21]
doi: 10.1371/journal.pone.0074630.t003
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(Figure 6A, image e). In all cell types, expression was observed
to be predominantly cytoplasmic. INTS12 expression in
controls and individuals with COPD was most evident in the
nuclei of alveolar pneumocytes (Figure 6B, images a and b)
and also in bronchial epithelial cells (Figure 6B, images e and
f).
When expression was investigated through different stages
of fetal development, the earliest embryonic samples (19 days)
exhibited weak nuclear and cytoplasmic immuno-positivity for
GSTCD (Figure 6C, top panel, images a and b), while
embryonic samples at 23 days development (images e and f)
showed strong protein expression in the developing blood
vessels and the outer region of the developing bronchioles.
Strong GSTCD expression was observed throughout the
pseudoglandular stage (images g-j), where expression was
noted in the nuclei of the developing pneumocytes of the early
bronchiole. Although high protein expression was still observed
in the blood vessels in tissue from the canalicular stage, at this
stage expression in the pneumocytes appeared to be reduced
compared with earlier developmental stages (images k-l).
When comparisons were made between samples, INTS12
expression remained generally consistent throughout all 3
developmental stages of fetal lung development, although in 2
out of the 6 early embryonic samples expression was
somewhat reduced (Figure 6C, panel 2, images a and c).
Expression was localised to the nucleus in most airway cell
types (Figure 6C, panel 2). Expression profiling of GSTCD and
INTS12 was also investigated using the BioGPS portal and this
revealed ubiquitous expression [22].
Comparison of GSTCD and INTS12 mRNA and protein
levels through lung development
To assess whether the expression of GSTCD and INTS12
through lung development at the protein level correlated with
that found at the mRNA level, a previously reported dataset
was mined to specifically interrogate these genes [23]. This
dataset contains samples analysed using gene expression
arrays to investigate expression patterns in the developing
human lung, specifically throughout the pseudoglandular (7-16
weeks) and the canalicular (17-26 weeks) stages. While
INTS12 expression was not observed to be altered significantly
between these stages, interestingly GSTCD expression
significantly decreased with age between the pseudoglandular
and canalicular stages (Table S6) as we also had observed at
the protein level (Figure 6C, panel 1, pseudoglandular images
g-j, canalicular images k-l).
Discussion
The aims of the studies described in this manuscript were to
(i) define the genetic architecture surrounding the SNPs at the
GSTCD/INTS12 locus at 4q24 previously found to be strongly
associated with lung function, (ii) assess how GSTCD and
INTS12 gene expression is regulated, (iii) analyse GSTCD and
INTS12 protein expression in non-diseased lung tissue and
lung tissue from individuals with COPD and (iv) assess whether
GSTCD or INTS12 protein expression changes during fetal
development.
The main conclusions were that lung function associated
SNPs in the region act as eQTL for INTS12 in multiple tissue
types including lymphoblastoid cell lines (LCL), brain and liver
Figure 5.  Correlation of GSTCD (A) and INTS12 (B) lung mRNA levels with percent predicted FEV1 in the lungs of 848
individuals (see Table S5 for patient demographics).  
doi: 10.1371/journal.pone.0074630.g005
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Figure 6.  GSTCD and INTS12 protein expression in human tissue.  Immunohistochemistry studies assessed GSTCD and
INTS12 protein expression in tissue sections from controls, individuals with COPD and from a range of fetal developmental stages.
All images x40 magnification. A: Representative images of GSTCD expression in lung tissue from three healthy donors (images a
and e) with matched isotype controls (iso, images c and g) and in lung tissue from three donors with COPD (images b and f) with
matched isotype controls (iso, images d and h). B: Representative images of INTS12 expression in lung tissue from three control
donors (images a and e) with matched isotype controls (iso, images c and g) and in lung tissue from three donors with COPD
(images b and f) with matched isotype controls (iso, images d and h). C: Panel 1: GSTCD expression in tissue from human fetuses
at a range of developmental stages: embryonic (19 days, a and b; 21 days, c and d; 23 days, e and f); pseudoglandular (10 weeks,
g and h; 12 weeks, i and j); canalicular (17 weeks, k; 19 weeks, l). Expression was observed to be increased through the
pseudoglandular stage. Panel 2: INTS12 expression in the same panel of tissue samples as described above. Isotype controls were
all negative (data not shown).
doi: 10.1371/journal.pone.0074630.g006
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and that both genes were widely expressed in cell types
relevant to airway function, including airway smooth muscle
cells and epithelial cells with evidence for coordinated gene
expression of GSTCD and INTS12. Finally mRNA levels in the
lung of both genes were correlated with lung function. It seems
likely that the association signal in this region is explained by
altered gene expression of INTS12 or GSTCD, or potentially
both genes.
Existing evidence suggests that transcript levels of GSTCD
are associated with variability in lung function from a study that
investigated lung mRNA expression levels among individuals
with variable degrees of airway obstruction [15]. This was
confirmed when we utilised data from a larger sample set that
aimed to identify lung eQTL and where lung function measures
were available on the majority of participants (n=848) (Figure
5). Findings from this study suggest a strong correlation
between a probe set targeting GSTCD with percent predicted
FEV1 and also, between the INTS12 probe set and percent
predicted FEV1.
It was particularly interesting that GSTCD protein expression
was observed to be altered through lung development,
decreasing between the pseudoglandular and canalicular
stages. Importantly, this correlates with a decrease in GSTCD
at the mRNA level between these same developmental stages,
as revealed by mining and specifically analysing the results of
a study previously reported by Melén et al. [23]. That protein
and mRNA levels of GSTCD are relatively higher in the
pseudoglandular stage when compared with the canalicular
stage is significant as it is through this stage of development
that airway smooth muscle cells, mast cells, T-lymphocytes
and dendritic cells all begin to appear within the lung
parenchyma [23]. Conversely, the reduction in GSTCD in the
canalicular phase coincides with alteration of the epithelium
and the surrounding mesenchyme.
Very little is known about the potential function of GSTCD.
As suggested by the name, part of this protein shares
homology with a GST motif which is present in a number of
other proteins. A protein homology search using NCBI BLAST
identified a number of other proteins sharing similar motifs with
GSTCD variants (Table S1A and 1B) with the closest match
being Eukaryotic Translation Elongation Factor 1, also known
as Aminoacyl-tRNA Synthetase-Interacting Multifunctional
Protein 3 (AIMP3). AIMP3 is an auxiliary component of the
macromolecular aminoacyl-tRNA synthase complex which is
reported to act as a molecular hub, linked to diverse signalling
pathways [24]. Also found to share homology with GSTCD
were isoforms of the Titin protein. Titin, previously known as
Connectin, is important in striated muscle contraction although
the expression and function of specific Titin isoforms have also
been reported in a range of smooth muscle types [25,26].
Interestingly, we also found homology with human Chloride
intracellular channel protein (hCLIC) 6. The role of hCLIC
proteins in the airways is unknown, although chloride
homeostasis has been shown to be important in a range of
respiratory conditions such as Cystic Fibrosis.
INTS12 is the smallest subunit of the Integrator complex [14]
that associates with the C-terminal domain of the largest
subunit of RNA polymerase II (RNAPII) at the promoter of small
nuclear (sn) RNA genes, where it mediates 3’ end processing
of snRNAs. RNAi-mediated deletion of INTS12 in Drosophila
S2 cells leads to snRNA mis-processing [27], suggesting a key
role for INTS12 within the Integrator complex. INTS12
possesses a highly conserved PHD-type zinc finger domain (a
motif often found in proteins involved in gene regulation), but
surprisingly this feature is not necessary for the snRNA
processing function of INTS12 in S2 cells [28]. Instead, a short
45 amino acid N-terminal domain appears both necessary and
sufficient to re-establish Integrator function in INTS12-depleted
cells and to mediate the binding and stabilisation of the larger
INTS1 subunit [28]. A protein homology search did not provide
additional insight into previously unrealised function (Table
S1C). The role of INTS12 in the mammalian respiratory system
has yet to be investigated, but a fundamental role for INTS12 in
mammalian cellular function is suggested by preliminary
evidence of pre-weaning lethality in transgenic mice lacking the
INTS12 gene (http://www.sanger.ac.uk/mouseportal/search?
query=colonyprefix:MALX).
From both experimental and in silico searches, some
interesting observations can be made regarding the
arrangement and regulation of GSTCD and INTS12. The data
presented suggest that under certain conditions in cells derived
from adult lung tissue, GSTCD and INTS12 are co-expressed.
This was observed in the Q-PCR expression studies performed
in airway-related cell types and PBMC (Figure 3B) and was
confirmed in microarray data from the lung eQTL study (Figure
3C). In addition the expression changes in response to TGFβ1
treatment also seem to be coordinated (Figure 4). Data from
Zebrafish suggest that the mean correlation coefficient r of all
the neighbouring gene pairs is 0.075, compared to r=0.03 in a
randomised genome of the same genes and expression values
[29]. Thus our observed correlation coefficient of 0.64 suggests
that GSTCD and INTS12 are correlated to a greater extent
than would be anticipated by chance for neighbouring genes.
The coordinated expression among GWAS signal is
interesting. It may suggest that trait associated variants reside
in regulatory regions that control the expression of multiple
genes, and it is possible that these regulated genes are part of
molecular pathways or networks underlying the trait.
Furthermore, the co-expression could be due to genes sharing
a bidirectional promoter, which are common in the human
genome; it is estimated that divergent genes regulated by
these account for 11% of all human genes [30,31]. Bidirectional
promoters typically (i) lack TATA boxes (only 8% of
bidirectional promoters contain a TATA box), (ii) have a high
GC content (66%), (iii) are enriched in CpG islands (77%)
[31,32], and (iv) about two thirds of non-overlapping
bidirectional promoters were found to be shorter than 300 bp in
length [31]. The GSTCD/INTS12 region exhibits many of these
characteristics: (i) they are divergent genes transcribed in
opposite directions, (ii) they were shown to be expressed in all
airway cell types tested, (iii) mRNA expression shows some
degree of correlation, (iv) the regions upstream of their TSS
lacked TATA boxes, and (v) the UCSC Genome Browser
suggests the intergenic region contains a CpG island and has
histone modification activity indicating active transcription.
However, the lack of a clear correlation between GSTCD and
GSTCD and INTS12 Regulation in the Human Lung
PLOS ONE | www.plosone.org 11 September 2013 | Volume 8 | Issue 9 | e74630
INTS12 expression patterns during lung development in utero
suggests additional, gene-specific regulatory pathways may
also exist.
The observed regulation by TGFβ1 is of particular relevance
within the context of several airway diseases, particularly
COPD and Idiopathic Pulmonary Fibrosis, in which TGFβ1 is a
key driver of fibrosis and extracellular matrix deposition.
Perhaps surprisingly, in silico analyses of putative transcription
factor binding sites did not reveal any matches between the
intergenic GSTCD/INTS12 shared promoter region and Smad-
induced transcription sites. However, interestingly we did
identify a number of other matches to transcription factors
including Serum Response Factor (SRF), NFκB, Glucocorticoid
Receptor (GR) and STAT3 which gives potential mechanistic
insight into regulatory pathways for these genes (see Table
S3). In human lung fibroblasts, SRF expression is dramatically
increased following exposure to TGFβ [33] thus this is a likely
mechanism for the TGFβ1-induced increase in GSTCD and
INTS12 mRNA in airway smooth muscle cells. STAT3 has
recently been suggested to be a central mediator of pulmonary
fibrosis via dysregulation of epithelial-mesenchymal
communication [34]. GR-mediated signalling occurs via both
gene repression and activation and it is unclear which
contributes to the anti-inflammatory effects of glucocorticoids.
However GR is able to associate directly with NFκB, for which
a consensus site was also observed in the intergenic GSTCD/
INTS12 region.
Taken together, the evidence presented in this paper
provides the first insight into the expression and regulation of
GSTCD and INTS12 in the airways. Whilst other genes at this
locus (notably NPNT) may also potentially contribute, the
evidence provided here suggests an important role for GSTCD
and/or INTS12. Knowledge of the transcriptional and
translational regulation and expression of these genes should
provide important insights into the underlying cause of the
observed strong association signal with lung function at this
locus on 4q24.
Materials and Methods
Ethics statement
All work was conducted with full ethical approval from the
sites involved. Details are given in the following sections.
Cell culture, treatment and preparation of total RNA
Primary human airway smooth muscle (HASM) cells were
isolated and prepared from three different donors then cultured
as described previously [35]. Ethical approval for the use of
primary cells was obtained from the Nottingham University
Hospitals local ethical committee (ref. EC00/165). Written
informed consent from the donor was obtained for use of this
sample in research.
Undifferentiated, adherent human bronchial epithelial cells
(HBEC) from three donors were commercially sourced from
Lonza (Basel, Switzerland), and cultured in bronchial epithelial
growth medium (BEGM) as per manufacturer’s instructions.
For analysis of altered gene expression via exposure to a
range of stimuli, cells were grown to 70 80% confluency and
the media changed to serum-free DMEM (for HASM) or BEGM
lacking hydrocortisone, Epithelial Growth Factor and
epinephrine (for HBEC) for 24h. Cells were exposed to the
following stimuli for 4h or 24h at the concentrations given:
TGFβ1 (10ng/ml), forskolin (10µM), U0126 (10µM), bradykinin
(1µM) and Lipopolysaccharide (LPS) (E. coli 026:B6) (1µg/ml).
All stimuli were obtained from Sigma Aldrich (Gillingham, UK).
For downstream analysis, cells were lysed and RNA
extracted using silica columns (RNeasy mini kit, Qiagen,
Crawley, UK). Total RNA was commercially obtained for
peripheral blood mononuclear cells (PBMC) of three donors
from 3H Biomedical (Uppsala, Sweden), and lung RNA from
three donors was obtained from Applied Biosystems/Ambion
(Warrington, UK).
5’ and 3’ Rapid Amplification of cDNA Ends (RACE)
RACE-ready cDNA was synthesised from total RNA (1µg)
from lung, HASM, undifferentiated HBEC and PBMC using the
GeneRacer kit as directed (Invitrogen, Paisley, UK). 5' and 3’
RACE used GeneRacer primers and gene-specific nested
primers for amplification. PCR products generated were also
cloned to further clarify the exon structure of the gene. Both
RACE and PCR products were sequenced using BigDye 3.1
(Applied Biosystems) in conjunction with an ABI 310 DNA
sequencer. Sequences were aligned to the human database
using the BLAST alignment tool (blast.ncbi.nlm.nih.gov).
Real-time PCR (Q-PCR)
mRNA levels of GSTCD/INTS12 were quantified using a
series of Q-PCR assays. Amplicons spanning exons 5–6 of
GSTCD and exons 7–8 of INTS12 were used with FAM/
TAMRA labelled TaqMan probes. cDNA was synthesised using
Superscript II (Invitrogen) and random hexamer primers as per
manufacturer’s instructions. RNA (1µg) was used in a 20µl
reverse transcription reaction Q-PCR was performed using
TaqMan gene expression master mix (Applied Biosystems) and
18S ribosomal RNA endogenous control (Applied Biosystems).
Data were corrected to the 18S housekeeper using the 2-ΔCt
method and normalised to lung mRNA expression using the 2-
ΔΔCt method.
Immunohistochemistry
Three non-diseased adult lung samples and three lung
samples from individuals with clinically diagnosed COPD were
collected from the Nottingham Health Science Biobank
(Nottingham, UK) with the required ethical approval (08/
H0407/1). Twelve fetal tissue samples were obtained from The
Human Developmental Biology Resource (Newcastle upon
Tyne and London, UK, www.hdbr.org) at diverse stages of
development, specifically 19, 21 and 23 days and 10, 12, 17
and 19 weeks post-conception. The Human Developmental
Biology Resource is a tissue bank which obtained ethical
approval from the NRES Committee London – Fulham (08/
H0712/34). Samples were consented for with written informed
consent from the donor or next of kin, in accordance with
national banking procedures and the UK Human Tissue Act
(2004). For all samples, 4µm whole tissue sections on glass
slides were de-paraffinized in Histo-clear (National Diagnostics,
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Dublin, Ireland) and hydrated using decreasing concentrations
of ethanol. Antigen retrieval was performed in a steamer for 20
minutes in sodium citrate buffer (pH 6.0), followed by an
endogenous peroxidase block for 5 minutes (Dako, Cambs,
UK). Slides were incubated with either a mouse polyclonal anti-
GSTCD antibody (H00079807, Abnova, Taiwan, China) (1:100)
or a rabbit polyclonal anti-INTS12 antibody (HPA035772,
Sigma Prestige Antibodies, Dorset, UK) (1:800) for 1 hour at
room temperature. Additional slides were stained in parallel
with normal mouse or rabbit IgG as respective matched isotype
controls (Invitrogen). The Dako Chemate Envision Detection Kit
(Dako) with DAB chromogen was used for detection. Sections
were then counterstained with Mayer’s Haematoxylin
(Surgipath, Cambs, UK), dehydrated and a coverslip mounted
using Vectamount (Vector Laboratories, Peterborough, UK).
Human liver or tonsil tissues were used as positive controls for
GSTCD and INTS12 staining, respectively, whilst a negative
control consisted of primary antibody substituted for antibody
diluent. Results were visualised using an Olympus BX14 light
microscope.
Statistical analysis
Differences in expression in Q-PCR experiments were
evaluated using ANOVA and Dunnett’s or Tukey’s post hoc test
as appropriate. Data were analysed using Prism v.5.01
(GraphPad software, La Jolla, CA). P<0.05 was considered a
statistically significant threshold.
Bioinformatics
Protein BLAST, BLASTP (http://blast.ncbi.nlm.nih.gov/
Blast.cgi?PAGE=Proteins), was used to align homologous
protein sequences against GSTCD and INTS12 protein
isoforms obtained from NCBI.
The region containing GSTCD-INTS12 was also investigated
using the UCSC genome Browser [36] (accessed at http://
genome.ucsc.edu/ in January 2013). More specifically,
annotations features from the ENCODE (The Encyclopaedia of
DNA Elements) Browser tracks [17] were used based on
experimental data from the ENCODE Project Consortium [37].
Publically available data [23,38] were utilised to see whether
GSTCD or INTS12 was differentially expressed during normal
human lung development. Previously, human fetal lung tissues
were obtained from National Institute of Child Health and
Human Development tissue databases and microarray profiled
to investigate the expression spanning different gestational
ages. RNA samples from 38 subjects (estimated gestational
age 7-22 weeks or 53-154 days post-conception) i.e.
pseudoglandular (gestational age, 7-16 weeks) and canalicular
(17-26 weeks) stages of development were included within the
dataset. These data are available at NCBI Gene Expression
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo), GSE14334.
The dataset was mined using Affymetrix probe sets;
220063_at, 1554518_at, 241126_at and 235387_at for GSTCD
and 218616_at for INTS12 expression.
The presence of eQTL at 4q24 for GSTCD and INTS12 was
investigated using the publically available eQTL datasets. The
lymphoblastoid cell lines eQTL website at http://
www.hsph.harvard.edu/liming-liang/software/eqtl/ was used
[21]. In addition, eQTL were also investigated using the
Pritchard Lab eQTL website from the University of Chicago at
http://eqtl.uchicago.edu/Home.html which hosts a browser
summarising results from a collection of published eQTL
studies.
Lung eQTL consortium methodologies
Subjects and genomic dataset.  Non-tumour lung tissues
were collected from patients who underwent lung resection
surgery at three participating sites: Laval University (Quebec
City, Canada), University of Groningen (Groningen, The
Netherlands), and University of British Columbia (UBC,
Vancouver, Canada). Whole-genome gene expression and
genotyping data were obtained from these specimens. Gene
expression profiling was performed using an Affymetrix custom
array testing 51,627 non-control probe sets and normalised
using RMA [39]. Genotyping was performed using the Illumina
Human1M-Duo BeadChip array. Following standard microarray
and genotyping quality controls, 1,111 patients were available
including 409 from Laval, 363 from Groningen, and 339 from
UBC. At Laval, lung specimens were collected from patients
undergoing lung cancer surgery and stored at the “Institut
Universitaire de Cardiologie et de Pneumologie de Québec”
(IUCPQ) site of the Respiratory Health Network, Tissue Bank
of the “Fonds de recherche du Québec – Santé”
(www.tissuebank.ca). Written informed consent was obtained
from all subjects and the study was approved by the IUCPQ
ethics committee. At Groningen, lung specimens were provided
by the local tissue bank of the Department of Pathology and
the study protocol was consistent with the Research Code of
the University Medical Center Groningen and Dutch national
ethical and professional guidelines (“Code of conduct; Dutch
Federation of Biomedical Scientific Societies”; http://
www.federa.org). At Vancouver, the lung specimens were
provided by the James Hogg Research Center Biobank at St
Paul’s Hospital and subjects provided written informed consent.
The study was approved by the ethics committees at the UBC-
Providence Health Care Research Institute Ethics Board.
Correlation of mRNA expression levels of GSTCD and
INTS12.  GSTCD was evaluated by three probe sets on the
Affymetrix array, while a single probe set was tested for
INTS12. The 1,111 individuals that passed all quality controls
filters were included in the analyses. The relationship between
the mRNA expression values of the different probe sets testing
GSTCD and INTS12 was assessed using Pearson’s
correlations.
Lung eQTL analysis for GSTCD and INTS12.  eQTL
analyses were performed in the 1,111 subjects. SNPs located
50 kilobases up- and down-stream of GSTCD and INTS12
were evaluated for association with their respective probe sets.
Age, gender, smoking status, and the study site were included
as covariates. Significant eQTL were those passing Bonferroni
correction considering the number of SNPs tested for each
gene.
Correlation of transcript levels with lung
function.  Correlations of transcript levels of GSTCD and
INTS12 in the lung with percent predicted FEV1 were
investigated using Pearson’s correlation. These analyses were
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performed with 848 subjects (a sub-set of the 1,111 available),
for whom lung function data were available and which excluded
individuals with airway disease which was non-obstructive or
not due to smoking. The demographics of these 848 individuals
are included in Table S5.
Supporting Information
Figure S1.  Annotated first exons of GSTCD Variant 2,
Variant 3 and INTS12 Variant 2 showing transcription start
sites (TSSs) identified by 5` RACE.  Nucleotide sequence of
the first exon of GSTCD Variant 2 (A), Variant 3 (B) and
INTS12 Variant 2 (C) showing in all cases the NCBI RefSeq
(build 37) start site and the start of intron 1 (accessed March
2013). Highlighted in green are the TSSs identified by 5’ RACE
with the red number above indicating the number of clones
observed to contain that specific TSS.
(DOCX)
Figure S2.  RT-PCR attempting to amplify GSTCD Variant 1
(NM_001031720.2) using primers mapping to exons 1 and
3.  No amplicon was detected after 40 cycles of PCR. Cycling
conditions were as follows: 94°C for 3 minutes, 35 cycles of
94°C for 45 seconds, 55°C for 30 seconds, and 72°C for 90
seconds. GAPDH was used as a housekeeping gene and a
product of the expected size of 508 bp is shown indicating the
RT-PCR assay was successful.
(DOCX)
Figure S3.  eQTL in the region containing GSTCD and
INTS12 at 4q24.  (A) shows eQTL identified in lymphoblastoid
cell lines using the eQTL website at http://
www.hsph.harvard.edu/liming-liang/software/eqtl/ (Liang et al.,
Genome research 23(4): 716-726) and (B) shows the eQTL
identified using the Pritchard Lab eQTL website at http://
eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/. Both (A) and (B) show
that eQTL exist for INTS12 in the region.
(PPTX)
Figure S4.  Lung eQTL for GSTCD and INTS12.  Shown are
the genotyped and imputed Single Nucleotide Polymorphism
(SNP) associations with GSTCD (purple) and INTS12 (green)
probe sets expression levels in the lungs of 1,111 individuals.
The scale on the left side Y axis shows the eQTL -log10 P
values, and the scale on the right hand side Y axis shows the
FEV1 association -log10P values. The red X represents the
sentinel SNP rs10516526 for association with FEV1. The three
probe sets for GSTCD were merged into gene level eQTL.
(DOCX)
Table S1.  A. Results from a Protein Homology Search of
GSTCD variant 1 (Accession NP_001026890.2). Search was
performed 30/01/2013 using BLAST (Basic Local Alignment
Search Tool) (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Accession: protein accession number; Chr: Chromosome; E
value: Expect value (E), a parameter that describes the number
of hits one can "expect" to see by chance when searching a
database of a particular size. B. Results from a Protein
Homology Search of GSTCD variant 2 (Accession
NP_079027.2). Search was performed 30/01/2013 using
BLAST (Basic Local Alignment Search Tool) (http://
blast.ncbi.nlm.nih.gov/Blast.cgi). Accession: protein accession
number; Chr: Chromosome; E value: Expect value (E), a
parameter that describes the number of hits one can "expect"
to see by chance when searching a database of a particular
size. C. Results from a Protein Homology Search of INTS12
(Accession NP_001135943.1). Search was performed
30/01/2013 using BLAST (Basic Local Alignment Search Tool)
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). Accession: protein
accession number; Chr: Chromosome; E value: Expect value
(E), a parameter that describes the number of hits one can
"expect" to see by chance when searching a database of a
particular size.
(DOCX)
Table S2.  A. 100 “resistant” smokers whole exome re-
sequencing. An exome re-sequencing project (results
unpublished) identified 1 non-synonymous SNP and 1
synonymous SNP in the coding regions of INTS12 which were
listed in dbSNP v137 but which were not in the 1000 Genomes
Project imputation reference panel. Both SNPs occurred as a
singleton call (1 heterozygote, no ALT allele homozygotes) in
the 100 individuals. rs146172950 is listed as a triallelic SNP in
dbSNP137 with reference allele C and alternative allele T
(frequency 0.049%) originally identified and submitted by the
NHLBI Exome Sequencing Project and alternative allele A
(frequency 0.016%) subsequently identified and submitted by
the 1000 Genomes Project. The alternative allele T was
observed in the 100 resistant smokers exome sequencing
project. rs144650579 is listed in dbSNP137 with reference
allele T and alternative allele C (frequency 0.085%) originally
identified and submitted by the NHLBI Exome Sequencing
Project. B. Targeted sequencing of GSTCD/INTS12 region.
A targeted sequencing study (results unpublished) identified
two intronic SNPs in GSTCD that do not appear in 1000
Genomes Project. All the SNPs identified in INTS12 appear in
1000 Genomes Project imputation reference panel.
rs113987854 is listed in dbSNP137 with reference allele T and
alternative allele A originally identified and submitted by
Complete Genomics. No population frequency is available for
this SNP (only counts based on one individual have been
submitted to dbSNP137).
(DOCX)
Table S3.  Transcription Factor sites identified via the
ENCODE project Chip-Seq assay in the region:
chr4:106609150-106654787 (hg build37).  ChromStart: Start
position in chromosome; ChromEnd: End position in
chromosome; Name: name of transcription factor; Score: Score
from 0-1000 (score for each peak, which reflects the posterior
probability of the peak belonging to the irreproducible group).
Search performed 30/01/2013.
(DOCX)
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Table S4.  ENCODE functional annotations of INTS12 eQTL
using HaploReg V2.  Shown are the predicted functional
annotation of the SNPs in terms of spanning a promoter,
enhancer site, DNase hypersensitivity site, proteins bound, or
the motifs changed and the corresponding cell type in which
this was detected. Gene name indicates the name of the gene
spanned by the SNP.
(XLSX)
Table S5.  Clinical characteristics of 848 individuals
participating in the eQTL study.  Pre: pre-bronchodilator;
Post: post-bronchodilator; Laval (Laval University, Canada),
Groningen (University of Groningen, The Netherlands) and
UBC (University of British Columbia, Canada) refer to the
cohorts recruited from each centre. Data are presented as
mean ± standard deviation.
(DOCX)
Table S6.  Fetal lung gene array data comparing GSTCD
and INTS12 expression during pseudoglandular and
canalicular stages of lung development.  logFC: log-fold
difference between 2 experimental groups; Average expression
is between all samples; t: t-statistic describing differential
expression; P Value: Unadjusted P value; Adjusted p value
controls for false discovery rate; Beta-coefficient: log-odds
ratio. n/s: no significance observed. Significant effects are
shown in bold and italicised.
(DOCX)
Acknowledgements
We are extremely grateful to Professor James Lowe (University
of Nottingham) for assistance in the use of human tissues
under the HTA and in assistance with the interpretation of
immunohistochemistry and stain optimisation. The human
embryonic and fetal material was provided by the Joint MRC/
Wellcome Trust (grant # 099175/Z/12/Z) Human
Developmental Biology Resource (www.hdbr.org). The authors
would like to thank the research staff at the Respiratory Health
Network Tissue Bank of the FRQS for their valuable
assistance. The UBC biobank that was used for the lung gene
expression analyses was developed by Drs J C Hogg, Don Sin
and PD Pare with the technical assistance of Dr Mark Elliott.
Author Contributions
Conceived and designed the experiments: MO SM KP CKB AH
EH CPN CES CS LVW MSA EM KU KH ML YB DSP MDT IS
IPH. Performed the experiments: MO SM KP CKB AH EH CPN
CES CS LVW MSA EM KU KH ML YB DSP MDT IS IPH.
Analyzed the data: MO SM KP CKB AH EH CPN CES CS LVW
MSA EM KU KH ML YB DSP MDT IS IPH. Contributed
reagents/materials/analysis tools: MO SM KP CKB AH EH
CPN CES CS LVW EM KU KH ML YB DSP MDT IS IPH.
Wrote the manuscript: MO CKB IPH. Approved the final version
to be published: MO SM KP CKB AH EH CPN CES CS LVW
MSA EM KU KH ML YB DSP MDT IS IPH. Revised the
manuscript critically for important intellectual content: MO SM
KP CKB AH EH CPN CES CS LVW MSA EM KU KH ML YB
DSP MDT IS IPH. Made a substantial contribution to the
conception or design of parts of the study: MO SM KP CKB AH
EH CPN CES CS LVW MSA EM KU KH ML YB DSP MDT IS
IPH. Made a significant contribution in data acquisition or the
analysis and interpretation of data: MO SM KP CKB AH EH
CPN CES CS LVW MSA EM KU KH ML YB DSP MDT IS IPH.
References
1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA et al. (2007) Global
strategy for the diagnosis, management, and prevention of chronic
obstructive pulmonary disease: GOLD executive summary. Am J
Respir Crit Care Med 176: 532-555. doi:10.1164/rccm.200703-456SO.
PubMed: 17507545.
2. Schünemann HJ, Dorn J, Grant BJ, Winkelstein W Jr., Trevisan M
(2000) Pulmonary function is a long-term predictor of mortality in the
general population: 29-year follow-up of the Buffalo Health Study.
Chest 118: 656-664. doi:10.1378/chest.118.3.656. PubMed: 10988186.
3. Hubert HB, Fabsitz RR, Feinleib M, Gwinn C (1982) Genetic and
environmental influences on pulmonary function in adult twins. Am Rev
Respir Dis 125: 409-415. PubMed: 7200340.
4. Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR et al. (2010)
Meta-analyses of genome-wide association studies identify multiple loci
associated with pulmonary function. Nat Genet 42: 45-52. doi:
10.1038/ng.500. PubMed: 20010835.
5. Repapi E, Sayers I, Wain LV, Burton PR, Johnson T et al. (2010)
Genome-wide association study identifies five loci associated with lung
function. Nat Genet 42: 36-44. doi:10.1038/ng.501. PubMed:
20010834.
6. Soler Artigas M, Loth DW, Wain LV, Gharib SA, Obeidat M et al. (2011)
Genome-wide association and large-scale follow up identifies 16 new
loci influencing lung function. Nat Genet 43: 1082-1090. doi:
10.1038/ng.941. PubMed: 21946350.
7. Hancock DB, Artigas MS, Gharib SA, Henry A, Manichaikul A et al.
(2012) Genome-wide joint meta-analysis of SNP and SNP-by-smoking
interaction identifies novel loci for pulmonary function. PLOS Genet 8:
e1003098. PubMed: 23284291.
8. Castaldi PJ, Cho MH, Litonjua AA, Bakke P, Gulsvik A et al. (2011) The
association of genome-wide significant spirometric loci with chronic
obstructive pulmonary disease susceptibility. Am J Respir Cell Mol Biol
45: 1147-1153. doi:10.1165/rcmb.2011-0055OC. PubMed: 21659657.
9. Soler Artigas M, Wain LV, Repapi E, Obeidat M, Sayers I et al. (2011)
Effect of 5 Genetic Variants Associated with Lung Function on the Risk
of COPD, and their Joint Effects on Lung Function. Am J Respir Crit
Care Med.
10. Board PG, Menon D (2013) Glutathione transferases, regulators of
cellular metabolism and physiology. Biochim Biophys Acta (. (2013))
PubMed: 23201197.
11. Hayes JD, Strange RC (2000) Glutathione S-transferase
polymorphisms and their biological consequences. Pharmacologist 61:
154-166. PubMed: 10971201.
12. Jakobsson PJ, Morgenstern R, Mancini J, Ford-Hutchinson A, Persson
B (1999) Common structural features of MAPEG -- a widespread
superfamily of membrane associated proteins with highly divergent
functions in eicosanoid and glutathione metabolism. Protein Sci 8:
689-692. PubMed: 10091672.
13. Hardin M, Zielinski J, Wan ES, Hersh CP, Castaldi PJ et al. (2012)
CHRNA3/5, IREB2, and ADCY2 are associated with severe chronic
obstructive pulmonary disease in Poland. Am J Respir Cell Mol Biol 47:
203-208. doi:10.1165/rcmb.2012-0011OC. PubMed: 22461431.
14. Baillat D, Hakimi MA, Näär AM, Shilatifard A, Cooch N et al. (2005)
Integrator, a multiprotein mediator of small nuclear RNA processing,
associates with the C-terminal repeat of RNA polymerase II. Cell 123:
265-276. doi:10.1016/j.cell.2005.08.019. PubMed: 16239144.
15. Bhattacharya S, Srisuma S, Demeo DL, Shapiro SD, Bueno R et al.
(2009) Molecular biomarkers for quantitative and discrete COPD
GSTCD and INTS12 Regulation in the Human Lung
PLOS ONE | www.plosone.org 15 September 2013 | Volume 8 | Issue 9 | e74630
phenotypes. Am J Respir Cell Mol Biol 40: 359-367. doi:10.1165/rcmb.
2008-0114OC. PubMed: 18849563.
16. Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM et al. (2010)
A map of human genome variation from population-scale sequencing.
Nature 467: 1061-1073. doi:10.1038/nature09534. PubMed: 20981092.
17. Rosenbloom KR, Dreszer TR, Pheasant M, Barber GP, Meyer LR et al.
(2010) ENCODE whole-genome data in the UCSC Genome Browser.
Nucleic Acids Res 38: D620-D625. doi:10.1093/nar/gkp961. PubMed:
19920125.
18. Creyghton MP, Cheng AW, Welstead GG, Kooistra T, Carey BW et al.
(2010) Histone H3K27ac separates active from poised enhancers and
predicts developmental state. Proc Natl Acad Sci U S A 107:
21931-21936. doi:10.1073/pnas.1016071107. PubMed: 21106759.
19. Saxonov S, Berg P, Brutlag DL (2006) A genome-wide analysis of CpG
dinucleotides in the human genome distinguishes two distinct classes
of promoters. Proc Natl Acad Sci U S A 103: 1412-1417. doi:10.1073/
pnas.0510310103. PubMed: 16432200.
20. Hao K, Bossé Y, Nickle DC, Paré PD, Postma DS et al. (2012) Lung
eQTLs to help reveal the molecular underpinnings of asthma. PLOS
Genet 8: e1003029. PubMed: 23209423.
21. Liang L, Morar N, Dixon AL, Lathrop GM, Abecasis GR et al. (2013) A
cross-platform analysis of 14,177 expression quantitative trait loci
derived from lymphoblastoid cell lines. Genome Res 23: 716-726. doi:
10.1101/gr.142521.112. PubMed: 23345460.
22. Wu C, Orozco C, Boyer J, Leglise M, Goodale J et al. (2009) BioGPS:
an extensible and customizable portal for querying and organizing gene
annotation resources. Genome Biol 10: R130. doi:10.1186/
gb-2009-10-11-r130. PubMed: 19919682.
23. Melén E, Kho AT, Sharma S, Gaedigk R, Leeder JS et al. (2011)
Expression analysis of asthma candidate genes during human and
murine lung development. Respir Res 12: 86. doi:
10.1186/1465-9921-12-86. PubMed: 21699702.
24. Park SG, Choi EC, Kim S (2010) Aminoacyl-tRNA synthetase-
interacting multifunctional proteins (AIMPs): a triad for cellular
homeostasis. IUBMB Life 62: 296-302. PubMed: 20306515.
25. Chi RJ, Simon AR, Bienkiewicz EA, Felix A, Keller TC 3rd (2008)
Smooth muscle titin Zq domain interaction with the smooth muscle
alpha-actinin central rod. J Biol Chem 283: 20959-20967. doi:10.1074/
jbc.M709621200. PubMed: 18519573.
26. Labeit S, Lahmers S, Burkart C, Fong C, McNabb M et al. (2006)
Expression of distinct classes of titin isoforms in striated and smooth
muscles by alternative splicing, and their conserved interaction with
filamins. J Mol Biol 362: 664-681. doi:10.1016/j.jmb.2006.07.077.
PubMed: 16949617.
27. Ezzeddine N, Chen J, Waltenspiel B, Burch B, Albrecht T et al. (2011)
A subset of Drosophila integrator proteins is essential for efficient U7
snRNA and spliceosomal snRNA 3'-end formation. Mol Cell Biol 31:
328-341. doi:10.1128/MCB.00943-10. PubMed: 21078872.
28. Chen J, Waltenspiel B, Warren WD, Wagner EJ (2013) Functional
analysis of the integrator subunit 12 identifies a microdomain that
mediates activation of the Drosophila integrator complex. J Biol Chem
288: 4867-4877. doi:10.1074/jbc.M112.425892. PubMed: 23288851.
29. Ng YK, Wu W, Zhang L (2009) Positive correlation between gene
coexpression and positional clustering in the zebrafish genome. Bmc
Genomics 10: 42-. PubMed: 19159490.
30. Liu B, Chen J, Shen B (2011) Genome-wide analysis of the
transcription factor binding preference of human bi-directional
promoters and functional annotation of related gene pairs. BMC. Syst
Biol 5 Suppl 1: S2.
31. Trinklein ND, Aldred SF, Hartman SJ, Schroeder DI, Otillar RP et al.
(2004) An abundance of bidirectional promoters in the human genome.
Genome Res 14: 62-66. PubMed: 14707170.
32. Lin JM, Collins PJ, Trinklein ND, Fu Y, Xi H et al. (2007) Transcription
factor binding and modified histones in human bidirectional promoters.
Genome Res 17: 818-827. doi:10.1101/gr.5623407. PubMed:
17568000.
33. Sandbo N, Kregel S, Taurin; S, Bhorade S, Dulin NO (2009) Critical
role of serum response factor in pulmonary myofibroblast differentiation
induced by TGF-beta. Am J Respir Cell Mol Biol 41: 332-338
34. Prêle CM, Yao E, O’Donoghue RJ, Mutsaers SE, Knight DA (2012)
STAT3: a central mediator of pulmonary fibrosis? Proc Am Thorac Soc
9: 177-182. doi:10.1513/pats.201201-007AW. PubMed: 22802294.
35. Liu B, Peel SE, Fox J, Hall IP (2010) Reverse mode Na+/Ca2+
exchange mediated by STIM1 contributes to Ca2+ influx in airway
smooth muscle following agonist stimulation. Respir Res 11: 168. doi:
10.1186/1465-9921-11-168. PubMed: 21126331.
36. Fujita PA, Rhead B, Zweig AS, Hinrichs AS, Karolchik D et al. (2011)
The UCSC Genome Browser database. Update 2011. Nucleic Acids
Res 39: D876-D882
37. Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR et
al. (2007) Identification and analysis of functional elements in 1% of the
human genome by the ENCODE pilot project. Nature 447: 799-816.
doi:10.1038/nature05874. PubMed: 17571346.
38. Kho AT, Bhattacharya S, Tantisira KG, Carey VJ, Gaedigk R et al.
(2010) Transcriptomic analysis of human lung development. Am J
Respir Crit Care Med 181: 54-63. doi:10.1164/rccm.200907-1063OC.
PubMed: 19815808.
39. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ et al.
(2003) Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics 4: 249-264. doi:
10.1093/biostatistics/4.2.249. PubMed: 12925520.
40. Veyrieras JB, Kudaravalli S, Kim SY, Dermitzakis ET, Gilad Y et al.
(2008) High-resolution mapping of expression-QTLs yields insight into
human gene regulation. PLOS Genet 4: e1000214. PubMed:
18846210.
41. Innocenti F, Cooper GM, Stanaway IB, Gamazon ER, Smith JD et al.
(2011) Identification, replication, and functional fine-mapping of
expression quantitative trait loci in primary human liver tissue. PLOS
Genet 7: e1002078. PubMed: 21637794.
42. Myers AJ, Gibbs JR, Webster JA, Rohrer K, Zhao A et al. (2007) A
survey of genetic human cortical gene expression. Nat Genet 39:
1494-1499. doi:10.1038/ng.2007.16. PubMed: 17982457.
43. Schadt EE, Molony C, Chudin E, Hao K, Yang X et al. (2008) Mapping
the genetic architecture of gene expression in human liver. PLOS Biol
6: e107. doi:10.1371/journal.pbio.0060107. PubMed: 18462017.
GSTCD and INTS12 Regulation in the Human Lung
PLOS ONE | www.plosone.org 16 September 2013 | Volume 8 | Issue 9 | e74630
